A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

Healthcare affordability was one of the major influencers of US midterm election outcomes. A recent poll revealed that more than half of US voters believe their healthcare costs have worsened under President Donald Trump's administration.

The analysis by health policy research organisation KFF was published a day after the 2026 midterm elections' results were announced. It found that 54% of midterm voters said the administration's policies had made their personal healthcare costs worse. Only 10% said their costs had improved.

Voters who said their healthcare costs had increased were more likely to support Democratic candidates. Among this group, 82% voted for Democratic candidates, compared to 16% who voted Republican.

The findings come as Democrats made significant gains in the November 3 midterms, winning control of both the House of Representatives as well as the Senate.

Democrats Have An Advantage On Healthcare

Also read: 2026 US Election Results: What Democrats’ Wins Mean For RFK Jr’s MAHA Movement And Vaccine Policy

KFF's analysis of the 2026 Voter Poll found that Democrats had a 19-percentage-point advantage over Republicans on healthcare.

When asked which party was better equipped to handle healthcare, 49% of voters chose Democrats, compared to 30% who chose GOP.

This shows a bigger jump from the 2024 presidential election, when Democratic presidential candidate Kamala Harris had a seven-point lead over Donald Trump on the same issue.

Democrats also held a narrow advantage on the economy as 43% of voters said that they trusted the party to handle it better, compared to 37% who chose Republicans. This marked a sharp reversal from 2024, when Trump had a 10-point advantage over Harris on the economy.

The healthcare advantage was also visible among independent voters. Among independents who said Trump's policies had made their healthcare costs worse, 69% voted for Democratic candidates for Congress.

Healthcare Affordability: A Major Election Concern

Also read: US Midterms: Where Did Voters Support Abortion Rights And Where Did They Reject Them?

Healthcare costs had emerged as a significant concern even before voters went to the polls. A separate KFF Health Tracking Poll conducted between September 16 and 21 found that six in 10 voters were worried about affording healthcare. This included 25% who were very worried and 35% who were somewhat worried.

The poll also found that 47% of voters considered healthcare costs an extremely significant issue for candidates to discuss during the midterm campaign.

Democratic candidates repeatedly highlighted healthcare affordability, criticising Republicans over the expiration of enhanced Affordable Care Act (ACA) premium tax credits and reductions in Medicaid spending included in the 2025 reconciliation law.

The enhanced ACA tax credits had helped lower insurance premiums for people purchasing coverage through the marketplaces. Their expiration raised concerns about higher insurance costs for many enrollees.

Medicaid spending reductions also became a key point of debate because of their implications for people relying on the government-funded health insurance programme.

Democrats' victory gives the party control of both chambers of Congress, creating opportunities to analyse Trump administration's healthcare policies and push for changes in insurance affordability and Medicaid. It also gives them room to bring reforms in reproductive healthcare, vaccine policies, and gender-affirming care.

However, implementing major policy changes may be difficult while Trump remains president, especially if legislation faces a presidential veto.

Pennsylvania recently announced that an unvaccinated individual tested positive for measles and died, becoming the sixth measles-associated death of 2026. The state's outbreak continues to expand as confirmed infections have now crossed 1,400 cases across 45 of its 67 counties.

The Pennsylvania Department of Health confirmed on November 4 that the resident was from Jefferson County. Officials did not release more details about the individual.

The latest death brings Pennsylvania's total to six this year. The state has recorded 1,467 confirmed measles cases across 45 counties, with 283 hospitalisations, according to its latest update.

The outbreak began in late April and has become one of the largest measles outbreaks in the United States in more than three decades.

Pennsylvania Reports Six Measles-Associated Deaths

Also read: New York Reports First Measles-Associated Death In 30 Years As Cases Continue To Rise

The six deaths confirmed by Pennsylvania health officials involved residents of three counties, in which three were from Lancaster County, two from Jefferson County and one from Mifflin County.

The state also addressed reports of a separate death involving a Franklin County resident in October. However, its investigation had not found evidence meeting the criteria to classify that death as measles-associated as of November 4.

Pennsylvania's definition requires a person to have clinical evidence of measles infection and a positive laboratory test, with death occurring within 30 days since symptom begins.

There is also a difference between state and federal death counts. Pennsylvania has confirmed six deaths, while the Centers for Disease Control and Prevention (CDC) has reported three measles-related deaths in its national tally as of October 29. The CDC is working on standard definition to ascertain how measles-associated deaths are classified across states.

US Reports Nearly 4,900 Measles Cases In 2026

Also read: US Midterm Elections 2026: Abortion, Medicaid, Measles And Healthcare Issues At Stake

Pennsylvania is at the centre of a wider resurgence of measles in the country. The CDC reported 4,852 confirmed measles cases in the US as of October 29, 2026. Of these, 96% were connected to outbreaks.

The state also saw a sharp increase in vaccination activity. Healthcare providers administered more than 61,000 measles, mumps and rubella (MMR) vaccine doses in October, more than twice the usual monthly number of approximately 25,000 doses.

Measles Is Life-Threatening

Measles is a highly contagious viral infection that spreads through the air when an infected person coughs or sneezes. The virus can remain infectious in the air or on surfaces for up to two hours.

Initial symptoms include high fever, cough, runny nose and red, watery eyes. A rash usually develops several days later, beginning on the face and spreading down the body.

Although many people recover, measles can cause serious complications, including pneumonia and encephalitis, or inflammation of the brain. It can also weaken the immune system and increase vulnerability to other infections.

The MMR vaccine remains the most effective protection. Two doses are approximately 97% effective against measles.

Pennsylvania health officials recommend that people check their vaccination records and speak to a healthcare provider if they are unsure whether they have received the recommended doses.

Infants aged six to 11 months living in or travelling to areas with sustained measles transmission may also be advised to receive an early vaccine dose. This does not replace the two routine doses recommended later.

The “Make America Healthy Again” (MAHA) movement, led by Robert F. Kennedy Jr., played a key role in helping Donald Trump win the presidency in 2024. Two years later, it faces growing political opposition, with Democrats challenging the Trump administration’s healthcare policies and Kennedy’s approach to public health.

In a historic shift in the balance of power, the Democratic Party has won control of both the House of Representatives and the Senate in the 3 November 2026 midterm elections, delivering a major setback to Trump and the Republican Party. The results gives Democrats greater scope to scrutinise and reverse the administration’s healthcare agenda, including Medicaid funding, federal health agency budgets and vaccine policies.

However, their ability to reverse existing policies will be constrained by presidential veto powers and the 60 Senate votes generally needed to overcome a filibuster. The new Congress is expected to take office in January 2027.

What Were The Key Healthcare Issues In The 2026 US Midterms?

Also read: 2026 US Election Results: What Annie Andrews And Amy Acton’s Wins Could Mean For Healthcare In America

• Healthcare costs: Rising insurance premiums, medical bills and prescription drug prices remained major concerns for voters.
• Medicaid: Funding changes and proposed work requirements raised concerns about millions potentially losing health coverage.
• Abortion rights: Ballot measures in Idaho, Nevada, Virginia and Missouri brought reproductive rights and access to abortion care into focus.
• Measles and vaccines: The US reported 4,852 confirmed measles cases across 47 jurisdictions as of October 29, 2026. Falling childhood vaccination coverage and changes to federal vaccine recommendations added to concerns.
• Prescription drug prices: Medicare drug price negotiations, Republican drug-pricing initiatives and rising spending on GLP-1 medications featured in the healthcare affordability debate.

Healthcare Candidates Who Won and Lost

More than 100 doctors, nurses and other healthcare professionals entered the 2026 US elections, in what was described as an unprecedented wave of candidates healthcare backgrounds.

Several Democratic candidates with healthcare and public health backgrounds secured major victories. These included:

• Dr. Annie Andrews: A practising paediatrician who defeated Darline Graham in South Carolina, becoming the first woman doctor elected to the US Senate.
• Dr. Amy Acton: A preventive medicine specialist and former director of the Ohio Department of Health who won the Ohio gubernatorial race.
• Dr. Abdul El-Sayed: An epidemiologist and former director of Detroit’s public health department who defeated Mike Rogers in Michigan’s Senate race.
• Xavier Becerra: The former US Health and Human Services (HHS) secretary under the Biden administration who won the California gubernatorial race.

Read More: US Midterms: Where Did Voters Support Abortion Rights And Where Did They Reject Them?

At the same time, several Republican candidates associated with healthcare and the MAHA movement also faced defeats. They included:

• Sen. Roger Marshall: An obstetrician-gynaecologist and founding member of the congressional MAHA Caucus who lost his Senate re-election bid in Kansas to Adam Hamilton.
• Zach Lahn: A prominent MAHA supporter who lost the Iowa gubernatorial race to Democrat Rob Sand.
• Vivek Ramaswamy: A former biotechnology executive who lost the Ohio gubernatorial race to Dr. Amy Acton.
• Rick Jackson: The founder and CEO of Jackson Healthcare who lost the Georgia gubernatorial race to Keisha Lance Bottoms.

Why RFK Jr.’s MAHA Movement Became An Election Issue

The MAHA movement, which promised to tackle chronic diseases and reform America's healthcare system, has faced criticism over Kennedy's approach to vaccines and public health. Changes to federal vaccine recommendations have become contentious amid a measles resurgence threatening the US' measles elimination status.

Pennsylvania reported 1,426 measles cases and five associated deaths as of October 30, 2026, its first measles fatalities in 35 years. The outbreak also triggered a public dispute between Kennedy and Governor Josh Shapiro over the deaths and claims about fetal tissue used in developing the MMR vaccine.

Beyond vaccines, MAHA's push to address ultra-processed foods, food additives and pesticides such as glyphosate has faced criticism over delays and concerns about corporate influence on food policy.

Autism has also emerged as a contentious issue. Trump's and Kennedy's September 2025 announcement on investigating possible autism causes, including a proposed link with acetaminophen use during pregnancy, and the CDC's July 2026 revision questioning the established scientific position on vaccines and autism drew criticism from health experts. Extensive evidence has found no causal link between vaccines and autism.

Looking ahead, Democratic lawmakers could use their control of Congress to scrutinise Kennedy's public health policies, demand scientific evidence behind federal health decisions and push for greater investment in vaccination and disease prevention programmes.

What Could Democratic Control Mean For Vaccine Policy?

Trump's changes to childhood vaccination recommendations could become a focus of congressional scrutiny. In August 2026, he signed an executive order recommending separate MMR shots once individual vaccines become available and separate appointments for childhood vaccinations, where feasible.

Healthcare professionals have warned that additional injections and appointments could complicate vaccination for families and increase the risk of delayed or missed doses.

The administration has also moved away from the universal hepatitis B birth-dose recommendation. Under revised CDC guidance adopted in December 2025, parents of infants born to mothers who test negative can decide with healthcare providers whether to administer the vaccine at birth or begin the series later.

Democrats could hold hearings and investigate changes to CDC vaccine recommendations, the restructuring of its Advisory Committee on Immunization Practices (ACIP), and the removal of vaccine experts from advisory panels. They could also scrutinise staffing and funding changes at federal health agencies.

However, congressional oversight does not automatically allow Democrats to reverse executive decisions or remove Kennedy as HHS secretary. Their influence will depend on their ability to pass legislation, shape federal funding and secure support for changes to the administration's healthcare policies.